Rusconi C, Barone A, Visentin A, Bianchi B, et al. Interim-PET predicts progression-free survival in stage IV Hodgkin lymphoma treated with upfront brentuximab vedotin-AVD. Leuk Lymphoma 2025 Jan 11:1-9. doi: 10.1080/10428194.2024.2446609.
PMID: 39797589